Previous 10 | Next 10 |
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Eric Urquhart/Shutterstock.com We’re starting off another day of trading with a look at the biggest pre-market stock movers for Wednesday! Moving stocks this morning are earnings reports, public stock off...
Cardiovascular Systems press release ( NASDAQ: CSII ): Q2 GAAP EPS of -$0.20 misses by $0.05 . Revenue of $61.5M (+4.1% Y/Y) misses by $3.1M . The Adjusted EBITDA loss increased to $3.7M from $3.0M in the prior year. Gross profit margin was 70.0%. As of Decembe...
Cardiovascular Systems, Inc. (CSI ® ) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today reported financial results for its second quarter, ended December 31, ...
Cardiovascular Systems ( NASDAQ: CSII ) is scheduled to announce Q2 earnings results on Thursday, February 9th, before market open. The consensus EPS Estimate is -$0.15 (+34.8% Y/Y) and the consensus Revenue Estimate is $63.06M (+6.7% Y/Y). Over the last 2 years, CSII has be...
Cardiovascular Systems, Inc. (NASDAQ: CSII) plans to announce its operating results for the quarter ended December 31, 2022 before the market opens on Thursday, February 9, 2023, and will host a conference call at 9:00 a.m. ET that day to discuss those results. Click here to access the live...
KAIZEN to assess safety and efficacy of peripheral orbital atherectomy to secure regulatory approval in Japan Cardiovascular Systems, Inc. (CSI) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with periph...
Summary AngioDynamics posted a pretty clean fiscal second quarter that was a little better than the sell-side expected, and that seemed to drive a meaningful relief rally for the beaten-down shares. Lackluster results from AngioVac/AlphaVac bear watching, given that they're important gr...
System includes mechanical and aspiration thrombectomy devices to treat peripheral vascular disease Cardiovascular Systems, Inc. (CSI ® ) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with ...
The following slide deck was published by Cardiovascular Systems, Inc. in conjunction with their 2023 Q1 earnings call. For further details see: Cardiovascular Systems, Inc. 2023 Q1 - Results - Earnings Call Presentation
Cardiovascular Systems, Inc. (CSI ® ) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today announced that management plans to present and host inve...
News, Short Squeeze, Breakout and More Instantly...
Cardiovascular Systems Inc. Company Name:
CSII Stock Symbol:
NASDAQ Market:
Cardiovascular Systems Inc. Website:
Cytek Biosciences Set to Join S&P SmallCap 600 Cytek Biosciences Set to Join S&P SmallCap 600 PR Newswire NEW YORK , April 25, 2023 /PRNewswire/ -- Cytek Biosciences Inc (NASD:CTKB) will replace Cardiovascular Systems Inc. (NASD:CSII) in the S&P S...
Largest randomized coronary atherectomy trial ever conducted Cardiovascular Systems, Inc. (CSI) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, announced today...
NEW YORK, NY / ACCESSWIRE / April 2, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: INDUS Realty Trust, Inc. (NASDAQ:I...